 |
|
|
| |
Emerging Patterns of Resistance to Integrase Inhibitors
|
| |
| |
Reported by Jules Levin
CROI Feb 8-2 2009, Montreal
Michael Miller*, R Danovich, M Witmer, B-Y Nguyen, H Teppler, J Zhao, R Barnard, D Hazuda, and for the HIV-1 Integrase Inhibitor Devt Teams, Protocol 004 Team, and BENCHMRK-1 and -2 Teams
Merck & Co, West Point, PA, US
Raltegravir (RAL) is the first licensed ARV that inhibits integration. Understanding resistance to this drug class is critical to maximizing the utility of the class in clinical practice, but data to date are still limited. Analysis of the phase 2 and 3 clinical trials of RAL has suggested the potential for several resistance pathways, each involving multiple mutations with different effects on susceptibility and replication capacity. This presentation will update and extend the analyses of integrase resistance from the clinical trials of RAL in both treatment-naive patients and patients with triple-class resistant HIV-1 infection.
http://www.retroconference.org/2009/data/files/webcast.htm. Click on Tuesday, then on Play Audio and Slides for Symposium: HIV Drug Resistance and Treatment Response Feb 10, 2009 4:00 PM
|
| |
|
|
|
|
|
